On September 8, 2020 Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, reported that the Company will participate in the following upcoming investor conferences (Press release, Abeona Therapeutics, SEP 8, 2020, View Source [SID1234564745]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

João Siffert, M.D., Chief Executive Officer, will conduct virtual one-on-one meetings with institutional investors at Citi’s 15th Annual BioPharma Virtual Conference on Wednesday, September 9, 2020.

Dr. Siffert will present at the Wells Fargo Virtual Healthcare Conference on Thursday, September 10, 2020 at 10:00 a.m. ET. A live webcast of the presentation will be available on the investor section of the Abeona Therapeutics website at www.abeonatherapeutics.com. The webcast replay will be available within 24 hours of the live presentation and will be accessible for 30 days.

On September 8, 2020 Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) ("Navidea" or the "Company"), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, reported that Mr. Jed Latkin, Chief Executive Officer, will present at the H.C. Wainwright 22nd Annual Global Investment Conference (Press release, Navidea Biopharmaceuticals, SEP 8, 2020, https://ir.navidea.com/news/detail/356/navidea-biopharmaceuticals-to-present-at-h-c-wainwright-22nd-annual-global-investment-conference [SID1234564744]). The virtual conference will be held on September 14-16, 2020. Mr. Latkin will present on Wednesday, September 16 at 10:30 a.m. EST.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of Navidea’s presentation are below. For those who wish to listen to the live webcast, please use the following link: View Source." target="_blank" title="View Source." rel="nofollow">View Source The webcast will be archived on Navidea’s investor relations website, View Source for 90 days following the live presentation.

Event: H.C. Wainwright 22nd Annual Global Investment Conference
Date: Wednesday, September 16, 2020
Time: 10:30 – 10:50 a.m. EDT
Location: Virtual Conference
Presentation Webcast Link: View Source

On September 8, 2020 Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for cancer and autoimmune/inflammatory diseases, reported the company will present at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020, at 10:30 a.m. ET/7:30 a.m. PT (Press release, Alpine Immune Sciences, SEP 8, 2020, View Source [SID1234564743]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available online in the investor relations section of the company’s website at View Source A replay of the presentation will be available on the company website for 90 days following the webcast.

On September 8, 2020 Neurocrine Biosciences, Inc. (Nasdaq: NBIX) reported that it will present at the Morgan Stanley 18th Annual Global Healthcare Conference at 1:30 p.m. ET on Monday, September 14, 2020 (Press release, Neurocrine Biosciences, SEP 8, 2020, View Source [SID1234564742]). Kevin Gorman, Chief Executive Officer, and Matt Abernethy, Chief Financial Officer, will present at the conference.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live presentation will be webcast and may be accessed on the Company’s website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.

On September 8, 2020 GlycoMimetics, Inc. (Nasdaq: GLYC) reported that Chief Executive Officer Rachel King will present at the upcoming H.C. Wainwright & Co 22nd Annual Global Investment Virtual Conference taking place September 14-16, 2020 (Press release, GlycoMimetics, SEP 8, 2020, https://ir.glycomimetics.com/news-releases/news-release-details/glycomimetics-present-upcoming-hc-wainwright-co-annual-global [SID1234564741]). The presentation will be available on the company’s website at the "Investors" tab for 30 days, beginning Monday, September 14 at 2:30 p.m. EDT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live webcast and subsequent archived recordings for the presentation, please visit the GlycoMimetics website at View Source